摘要
目的研究经血来源的间充质干细胞(MenSCs)对子宫内膜血管生成的调节作用及分子机制。方法应用MenSCs来源的条件培养液(0,500,1000,2000μl)分别培养原代培养的子宫内膜基质细胞,共作用48 h后,采用实时PCR和In Cell-Western的方法对子宫内膜间质细胞中CXCL1的表达进行分析。将子宫内膜基质细胞(组1)、MenSCs和子宫内膜基质细胞(组2)、MenSCs和子宫内膜基质细胞添加CXCL1中和抗体(组3)放入Transwell小室上层,人脐静脉内皮细胞(HUVECs)放入小室下层培养,共同培养48 h后,检测HUVECs的微管形成情况。结果随着MenSCs来源的条件培养液的浓度增加,子宫内膜基质细胞中的CXCL1表达依赖性增加,差异有统计学意义(P<0.05)。组1、组2、组3微管形成的节点数分别为(19.73±2.26)、(37.23±2.58)、(11.29±1.32)。组2的微管形成能力明显好于组1(P<0.05),当添加了CXCL1中和抗体后,组3的微管形成能力同组2比较明显下降(P<0.05)。结论MenSCs可以通过促进子宫内膜基质细胞合成CXCL1来调控子宫内膜的血管形成,在子宫内膜再生过程中具有重要作用。
Objective To study the regulation effect and molecular mechanism of mesenchymal stem cells derived from menstrual blood(MenSCs)on endometrial angiogenesis.Methods Primary cultured endometrial stromal cells(ESCs)were cultured in MenSCs-derived conditionals(0,500,1000,2000μl)for 48 hours.Real-time PCR and In Cell-Western were used to analyze the expression of CXCL1 in endometrial stromal cells.ESCs(group 1),MenSCs and ESCs(group 2),MenSCs and ESCs with CXCL1 neutralizing antibody(group 3)were placed in the upper part of the Transwell compartment,and human umbilical vein endothelial cells(HUVECs)were cultured in the lower part of the compartment.After co-culture for 48 hours,the microtubule formation of HUVECs was detected.Results The expression of CXCL1 dependence in ESCs was enhanced with the increase of the concentration of conditioned medium from MenSCs,and the difference was statistically significant(P<0.05).The node numbers of microtubule formation in group 1,group 2,and group 3 were(19.73±2.26),(37.23±2.58),and(11.29±1.32),respectively.The microtubule formation ability of group 2 was significantly better than that of group 1(P<0.05).When CXCL1 neutralizing antibody was added,the microtubule formation ability of group 3 was significantly decreased com⁃pared with that of group 2(P<0.05).Conclusion MenSCs regulate endometrial angiogenesis by promoting the synthesis of CXCL1 in ESCs,which play an important role in endometrial regeneration.
作者
马超
徐汶津
关长吉
MA Chao;XU Wen-jin;GUAN Chang-ji(China Medical University,Shenyang,Liaoning 110000,China;Affiliated Reproductive Hospital of China Medical University,Key Laboratory of Reproductive Health and Genetic Medicine,National Health and Family Planning Commission,Shenyang,Liaoning 110000,China)
出处
《中国妇幼保健》
CAS
2023年第10期1886-1890,共5页
Maternal and Child Health Care of China
基金
辽宁省科学技术计划项目(2018225087,2019-ZD-1093)。